基于68Ga-PSMA PET/CT的前列腺床复发图谱:根治性前列腺切除术后挽救性放疗勾画指南的临床意义
本研究为单中心回顾性分析,纳入226例根治性前列腺切除术后生化持续或生化复发且68Ga-PSMA PET显示前列腺床复发的患者,评估基于RTOG的前列腺床临床靶区对PSMA阳性复发的覆盖情况。在127例复发局限于前列腺床(miTrN0M0)的患者中,完全覆盖68例(53%)、部分覆盖43例(34%)、未覆盖16例(13%);完全覆盖与较小肿瘤体积(P=0.043)、无直肠/膀胱壁受累(P=0.03)和较低miTNM分期(P=0.035)相关,但与较低血清PSA水平无关(P=0.979)。作者认为68Ga-PSMA PET可作为指导术后生化复发或生化持续患者前列腺床挽救性放疗规划的有价值工具,这些数据应纳入前列腺床勾画指南的重新定义。
要点
- 在127例复发限于前列腺床的患者中,基于RTOG的临床靶区完全覆盖PSMA阳性复发者68例(53%),部分覆盖43例(34%),未覆盖16例(13%)。
- 完全覆盖与较小肿瘤体积(P=0.043)、无直肠/膀胱壁受累(P=0.03)和较低miTNM分期(P=0.035)相关,与较低血清PSA水平无关(P=0.979)。
- 作者认为68Ga-PSMA PET可作为指导术后生化复发或生化持续患者前列腺床挽救性放疗规划的有价值工具。
核心结论
- 作者认为68Ga-PSMA PET可作为指导术后生化复发或生化持续患者前列腺床挽救性放疗规划的有价值工具,这些数据应纳入前列腺床勾画指南的重新定义。
研究设计与样本
- 单中心回顾性分析,纳入根治性前列腺切除术后生化持续或生化复发且68Ga-PSMA PET显示前列腺床复发的患者226例。
- 前列腺床复发由核医学医师勾画,临床靶区由放射肿瘤科医师依据勾画指南在68Ga-PSMA PET上勾画,双方互盲。
- PSMA复发被RTOG临床靶区覆盖情况分为完全覆盖、部分覆盖和未覆盖三类,并评估不同miTNM分期患者的PSMA复发模式差异。
主要发现
- 226例中,127例PSMA复发局限于前列腺床(miTrN0M0),30例有盆腔淋巴结病变(miTrN1M0),32例有盆腔外病变(miTrN0M1),37例同时有盆腔淋巴结和盆腔外病变(miTrN1M1)。
- 在miTrN0M0队列中,127例中12例(9%)复发累及直肠壁,4例(3%)累及膀胱壁。
- 在127例miTrN0M0患者中,PSMA阳性前列腺床复发被临床靶区完全覆盖68例(53%)、部分覆盖43例(34%)、未覆盖16例(13%)。
- 完全覆盖与较小肿瘤体积(P=0.043)、无直肠/膀胱壁受累(P=0.03)和较低miTNM分期(P=0.035)相关,但与较低血清PSA水平无关(P=0.979)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to analyze the patterns of prostate bed (PB) recurrence in prostate cancer patients experiencing prostate-specific antigen (PSA) persistence (BCP) or biochemical recurrence (BCR) after radical prostatectomy using 68Ga-PSMA-11 PET/CT (68Ga-PSMA PET) in relation to the Radiation Therapy Oncology Group (RTOG) clinical target volumes (CTVs). Methods: This single-center, retrospective analysis included patients with BCP or BCR after radical prostatectomy and PB recurrence on 68Ga-PSMA PET. The PB recurrences were delineated by nuclear medicine physicians, the CTVs by radiation oncologists contouring guidelines on the 68Ga-PSMA PET, respectively, masked from each other. The coverage of the 68Ga-PSMA PET recurrence was categorized as PSMA recurrence completely covered, partially covered, or not covered by the RTOG-based CTV. Further, we evaluated the differences in PSMA recurrence patterns among patients with different 68Ga-PSMA PET staging (miTNM). Mann-Whitney U tests, the chi-square test, and Spearman (ρ) correlation analysis were used to investigate associations between CTV coverage and 68Ga-PSMA PET-based tumor volume, serum PSA levels, miTNM, and rectal/bladder involvement. Results: A total of 226 patients were included in the analysis; 127 patients had PSMA recurrence limited to the PB (miTrN0M0), 30 had pelvic nodal disease (miTrN1M0), 32 had extrapelvic disease (miTrN0M1), and 37 had both pelvic nodal disease and extrapelvic disease (miTrN1M1). In the miTrN0M0 cohort, the recurrence involved the rectal and bladder walls in 12 of 127 (9%) and 4 of 127 (3%), respectively. The PSMA-positive PB recurrences were completely covered by the CTV in 68 of 127 patients (53%), partially covered in 43 of 127 (34%), and not covered in 16 of 127 (13%). Full coverage was associated with a smaller tumor volume (P = 0.043), a lack of rectal/bladder wall involvement (P = 0.03), and lower miTNM staging (P = 0.035) but not with lower serum PSA levels (P = 0.979). Conclusion: Our study suggests that 68Ga-PSMA PET can be a valuable tool for guiding salvage radiation therapy (SRT) planning directed to the PB in the setting of postoperative BCR or BCP. These data should be incorporated into the redefinition of PB contouring guidelines.
引用
- Sonni I, Dal Pra A, O'Connell DP, et al. 68Ga-PSMA PET/CT-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. J Nucl Med. 2023. PMID: 36759200. doi:10.2967/jnumed.122.265025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。